Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
HemoGenyx Pharmaceuticals Plc ( (GB:HEMO) ) has shared an announcement.
Hemogenyx Pharmaceuticals has been invited to present at the DCNY Summit, a prestigious event that connects policymakers, investors, and corporate leaders, offering a platform to showcase their clinical progress and pipeline, including a Phase I trial for CAR-T cell therapy targeting acute myeloid leukemia. This opportunity is expected to enhance Hemogenyx’s visibility among influential stakeholders and potentially secure growth capital, thereby advancing its mission to transform cancer treatment.
More about HemoGenyx Pharmaceuticals Plc
Hemogenyx Pharmaceuticals is a publicly traded clinical stage biopharmaceutical company headquartered in London, with US subsidiaries in New York City. The company focuses on developing new medicines and treatments for blood and autoimmune diseases, leveraging distinct product candidates and platform technologies for novel product development.
Average Trading Volume: 97,842
Technical Sentiment Signal: Buy
Current Market Cap: £45.09M
For detailed information about HEMO stock, go to TipRanks’ Stock Analysis page.